Detalle Publicación

Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer

Autores: Mirza, M. R.; Monk, B. J.; Herrstedt, J.; Oza, A. M.; Mahner, S.; Redondo, A.; Fabbro, M.; Ledermann, J. A.; Lorusso, D.; Vergote, I.; Ben-Baruch, N. E.; Marth, C.; Madry, R.; Christensen, R. D.; Berek, J. S.; Dorum, A.; Tinker, A. V.; du Bois, A.; González Martín, Antonio; Follana, P.; Benigno, B.; Rosenberg, P.; Gilbert, L.; Rimel, B. J.; Buscema, J.; Balser, J. P.; Agarwal, S.; Matulonis, U. A.; ENGOT-OV16 NOVA Investigators
Título de la revista: NEW ENGLAND JOURNAL OF MEDICINE
ISSN: 1533-4406
Volumen: 375
Número: 22
Páginas: 2154-2164
Fecha de publicación: 2016
Resumen:
Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer among those receiving niraparib than among those receiving placebo, regardless of the presence or absence of gBRCA mutations or HRD status, with moderate bone marrow toxicity. (Funded by Tesaro; ClinicalTrials.gov number, NCT01847274 .
Impacto:
Google Scholar